Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Girentuximab, an antibody targeting CA9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clivatuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Onartuzumab, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ganitumab, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fulranumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabalumab, an antibody targeting TNFSF13B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lampalizumab, an antibody targeting CFD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fasinumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Actoxumab, an antibody targeting Clostridium difficile Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bococizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vadastuximab, an antibody targeting SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rovalpituzumab, an antibody targeting DLL3.